Children's Hospital of Chongqing Medical University
Beijing Children's Hospital
Second Xiangya Hospital of Central South University
Shenzhen Children's Hospital
Nanjing Children's Hospital
Jilin University
Children's Hospital of Fudan University
Age
6–18
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age ≥6 years and \<18 years, with body weight ≥20 kg
Meets the 2019 European League Against Rheumatism (EULAR) and American College of Rheumatology (ACR) classification criteria for Systemic Lupus Erythematosus (SLE)
Renal biopsy confirming Lupus Nephritis class III, IV, III+V, or IV+V according to the International Society of Nephrology / Renal Pathology Society (ISN/RPS) classification
At screening: 24-hour urinary protein ≥1.0 g (or ≥25 mg/kg), or urine protein-to-creatinine ratio (UPCR) ≥1.0 g/g
White blood cell count ≥3.0 × 10⁹/L and lymphocyte count ≥1.0 × 10⁹/L
No prior intravenous methylprednisolone pulse therapy before enrollment, and glucocorticoid exposure ≤2 weeks before enrollment, with a maximum prednisone-equivalent dose ≤30 mg/day (or ≤1 mg/kg/day)
Written informed consent obtained and good treatment compliance expected
You may not be if
Uncertain diagnosis of SLE, genetically confirmed monogenic lupus, or a history of immunodeficiency
Severe infection, including hepatitis C, active hepatitis B, HIV infection, tuberculosis infection, severe fungal infection, etc.
Severe cardiac insufficiency (NYHA functional class ≥ II)
Severe pulmonary involvement, including pulmonary hemorrhage, respiratory failure, pulmonary embolism, or other conditions requiring respiratory support
Estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73 m²
Severe gastrointestinal bleeding, pancreatitis, or hepatic lesions
Patients deemed by the investigator to be unsuitable for participation in this trial
